ENDOVASCULAR ABLATION OF THE RIGHT GREATER SPLANCHNIC NERVE IN Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF: Feasibility Study: Randomized Controlled Feasibility Trial- Rebalance HF Study
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
Sponsor: Axon Therapies, Inc.
Enrolling: Male and Female Patients
Clinic Visits: 4
IRB Number: AAAT5292
U.S. Govt. ID: NCT04592445
Contact: Dawn Scotto: 212-305-1368 / caccresearch@cumc.columbia.edu
Additional Study Information: The objective of this clinical evaluation is to assess the safety and initial effectiveness of an interventional procedure involving ablation of the right greater splanchnic nerve (GSN) in subjects having heart failure with preserved ejection fraction (HFpEF).
This study is closed
Investigator
Nir Uriel, MD, MSc
Do You Qualify?
Are you 50 years old or older? Yes No
Do you have a Left Ventricular Ejection Fraction less than 50%? Yes No
Do you have heart failure? Yes No
Have you had a recent Heart failure hospitalization or been given IV diuretics or had an elevated NTproBNP in the past 6 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Dawn Scotto
caccresearch@cumc.columbia.edu
212-305-1368
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE